Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liao, Tsai Ling ^a,b   Lin, Chin Fu ^a   Chen, Yi Ming ^a,b,c   Liu, Hung Jen ^b   Chen, Der Yuan ^a,b,c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ANTIBIOTIC RESISTANCE; ATYPICAL MYCOBACTERIOSIS; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; DRUG EFFECT; ENDEMIC DISEASE; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DRUG RESISTANCE, BACTERIAL; ENDEMIC DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84978411830     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29443     Document Type: Article

References (42)

1. van Ingen, J., Boeree, M. J., Dekhuijzen, P. N. R. & Van Soolingen, D. Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. Clin Microbiol Infect 15, 888-893 (2009).
2. Griffith, D. E., Aksamit, T. & Brown-Elliott, B. A. et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175, 367-416 (2007).
3. Gopinath, K. & Singh, S. Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger? PLoS Negl Trop Dis 4, e615 (2010).
4. Chien, J. Y., Lai, C. C., Sheng, W. H., Yu, C. J. & Hsueh, P. R. Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000-2012. Emerg Infect Dis 20, 1382-1385 (2014).
5. Schluger, N. W. The growing challenge of nontuberculous mycobacteria. Chest 146, 529-530 (2014).
6. Centers for Disease Control, Ministry of Health and Welfare, R. O. C. (Taiwan). 2013-2014 Centers for Disease Control Annual Report. (2014).
7. Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M. & Gabriel, S. E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46, 2287-2293 (2002).
8. Brode, S. K., Jamieson, F. B. & Ng, R. et al. Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest 146, 563-572 (2014).
9. Liao, T. L., Lin, C. H., Shen, G. H., Chang, C. L., Lin, C. F. & Chen, D. Y. Risk for mycobacterial disease among patients with rheumatoid arthritis, Taiwan, 2001-2011. Emerg Infect Dis 21, 1387-1395 (2015).
10. Smolen, J. S., Landewe, R. & Breedveld, F. C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73, 492-509 (2014).
11. Winthrop, K. L., Chang, E., Yamashita, S., Iademarco, M. F. & LoBue, P. A. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15, 1556-1561 (2009).
12. Winthrop, K. L., Baxter, R. & Liu, L. et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72, 37-42 (2013).
13. Kendall, B. A. & Winthrop, K. L. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med 34, 87-94 (2013).
14. Brode, S. K., Daley, C. L. & Marras, T. K. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis 18, 1370-1377 (2014).
15. Bodle, E. E., Cunningham, J. A., Della-Latta, P., Schluger, N. W. & Saiman, L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 14, 390-396 (2008).
16. Mirsaeidi, M., Machado, R. F., Garcia, J. G. & Schraufnagel, D. E. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS One 9, e91879 (2014).
17. Kartalija, M., Ovrutsky, A. R. & Bryan, C. L. et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 187, 197-205 (2013).
18. Simons, S., van Ingen, J. & Hsueh, P. R. et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 17, 343-349 (2011).
19. Yeh, J. J., Wang, Y. C. & Lin, C. L. et al. Nontuberculous mycobacterial infection is associated with increased respiratory failure: a nationwide cohort study. PLoS One 9, e99260 (2014).
20. Bongartz, T., Nannini, C. & Medina-Velasquez, Y. F. et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62, 1583-1591 (2010).
21. J. A., Yang, J., Moon & S. H., Chang et al. Comparison of the Clinical Characteristics of Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease. Ann Rheum Dis 74, 1012 (2015).
22. Davas, E. M., Alexiou, I. & Boulbou, M. et al. Co-morbidities increase the risk of serious infections in patients with rheumatoid arthritis treated with TNF alpha inhibitors. J Infect 57, 418-420 (2008).
23. Caplan, L., Wolfe, F., Russell, A. S. & Michaud, K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 34, 696-705 (2007).
24. Dixon, W. G., Abrahamowicz, M. & Beauchamp, M. E. et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 71, 1128-1133 (2012).
25. Brode, S. K., Jamieson, F. B. & Ng, R. et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax 70, 677-682 (2015).
26. Kourbeti, I. S., Ziakas, P. D. & Mylonakis, E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58, 1649-1657 (2014).
27. Baddley, J. W., Winthrop, K. L. & Chen, L. et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis 73, 1942-1948 (2014).
28. Salmon-Ceron, D., Tubach, F. & Lortholary, O. et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70, 616-623 (2011).
29. Lutt, J. R., Pisculli, M. L. & Weinblatt, M. E. et al. Severe Nontuberculous Mycobacterial Infection in 2 Patients Receiving Rituximab for Refractory Myositis. J Rheumatol 35, 1683-1686 (2008).
30. Shao, Y., Chen, C. & Song, H. et al. The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Negl Trop Dis 9, e0003623 (2015).
31. Koh, W. J., Jeong, B. H. & Jeon, K. et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare In M. avium complex lung disease. Chest 142, 1482-1488 (2012).
32. Griffith, D. E., Brown-Elliott, B. A. & Langsjoen, B. et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 174, 928-934 (2006).
33. Yang, S. C., Hsueh, P. R. & Lai, H. C. et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 47, 1958-1962 (2003).
34. Lee, M. R., Cheng, A. & Lee, Y. C. et al. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates. J Antimicrob Chemother 67, 222-225 (2012).
35. Andrejak, C., Thomsen, V. O. & Johansen, I. S. et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 181, 514-521 (2010).
36. Au, K., Reed, G. & Curtis, J. R. et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70, 785-791 (2011).
37. Ledingham, J. & Deighton, C. British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 44, 157-163 (2005).
38. Arnett, F. C., Edworthy, S. M. & Bloch, D. A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-324 (1988).
39. Yamakawa, H., Takayanagi, N. & Miyahara, Y. et al. Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis. J Rheumatol 40, 1307-1315 (2013).
40. Huang, C. C., Chen, J. H. & Hu, S. T. et al. Combined rpoB duplex PCR and hsp65 PCR restriction fragment length polymorphism with capillary electrophoresis as an effective algorithm for identification of mycobacterial species from clinical isolates. BMC Microbiol 12, 137 (2012).
41. Metchock, B. G., Nolte, F. S. & Wallace, R. J. Mycobacterium. In: Murray, P. R., Baron, E. J., Pfaller, M. A., Tenover, F. C. & Yolken, R. H. editor. Manual of clinical microbiology. 7th ed. Washington, DC: ASM Press p.399-437 (1999).
42. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes; approved standard. 2nd ed. Document M24-A2. Wayne, PA: CLSI; (2011).